Peroxisome proliferator‐activated receptor‐γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type‐2 diabetic rodents
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Thiazolidinediones (TZDs) are synthetic agonists of the ligand‐activated transcription factor peroxisome proliferator‐activated receptor‐γ (PPARγ). TZDs are known to curtail inflammation associated with peripheral organ ischemia. As inflammation precipitates the neuronal death after stroke, we tested the efficacy of TZDs in preventing brain damage following transient middle cerebral artery occlusion (MCAO) in adult rodents. As hypertension and diabetes complicate the stroke outcome, we also evaluated the efficacy of TZDs in hypertensive rats and type‐2 diabetic mice subjected to transient MCAO. Pre‐treatment as well as post‐treatment with TZDs rosiglitazone and pioglitazone significantly decreased the infarct volume and neurological deficits in normotensive, normoglycemic, hypertensive and hyperglycemic rodents. Rosiglitazone neuroprotection was not enhanced by retinoic acid × receptor agonist 9‐cis‐retinoic acid, but was prevented by PPARγ antagonist GW9662. Rosiglitazone significantly decreased the post‐ischemic intercellular adhesion molecule‐1 expression and extravasation of macrophages and neutrophils into brain. Rosiglitazone treatment curtailed the post‐ischemic expression of the pro‐inflammatory genes interleukin‐1β, interleukin‐6, macrophage inflammatory protein‐1α, monocyte chemoattractant protein‐1, cyclooxygenase‐2, inducible nitric oxide synthase, early growth response‐1, CCAAT/enhancer binding protein‐β and nuclear factor‐kappa B, and increased the expression of the anti‐oxidant enzymes catalase and copper/zinc‐superoxide dismutase. Rosiglitazone also increased the expression of the anti‐inflammatory gene suppressor of cytokine signaling‐3 and prevented the phosphorylation of the transcription factor signal transducer and activator of transcription‐3 after focal ischemia. Thus, PPARγ activation with TZDs might be a potent therapeutic option for preventing inflammation and neuronal damage after stroke with promise in diabetic and hypertensive subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reversible middle cerebral artery occlusion without craniectomy in rats.
Longa, E. Z., Weinstein, P. R., Carlson, S., & Cummins, R. (1989) · Stroke · doi:10.1161/01.str.20.1.84 · Cited by 7,463
Peroxisome proliferator-activated receptors: insight into multiple cellular functions
Escher, P., & Wahli, W. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00231-6 · Cited by 491 · cited 3×
“When a ligand binds to PPAR, it dimerizes with RXR to form a complex that binds to PPREs on DNA to initiate or trans-repress the transcription of target genes (Escher and Wahli 2000).”
BackgroundReceptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Self-citationPark, E. J., Park, S. Y., Joe, E.-H., & Jou, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210819200 · Cited by 214
Cited by
Alternatively activated microglia and macrophages in the central nervous system
Franco, R., & Fernández-Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 650
Post‐ischemic brain damage: pathophysiology and role of inflammatory mediators
Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., & Corasaniti, M. T. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06766.x · Cited by 459
Transient Focal Ischemia Induces Extensive Temporal Changes in Rat Cerebral MicroRNAome
Dharap, A., Bowen, K., Place, R., Li, L.-C., & Vemuganti, R. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.157 · Cited by 445
Self-citationMechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Self-citationROS and Brain Diseases: The Good, the Bad, and the Ugly
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., & Buga, A.-M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/963520 · Cited by 427
Role of Inflammation and Its Mediators in Acute Ischemic Stroke
Jin, R., Liu, L., Zhang, S., Nanda, A., & Li, G. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9508-6 · Cited by 418
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 369
Cuartero, M. I., Ballesteros, I., Moraga, A., Nombela, F., Vivancos, J., Hamilton, J. A., Corbí, Á. L., Lizasoain, I., & Moro, M. A. (2013) · Stroke · doi:10.1161/strokeaha.113.002470 · Cited by 344
Systemic infection, inflammation and acute ischemic stroke
McColl, B. W., Allan, S. M., & Rothwell, N. J. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.019 · Cited by 318
Neuronal Interleukin-4 as a Modulator of Microglial Pathways and Ischemic Brain Damage
Zhao, X., Wang, H., Sun, G., Zhang, J., Edwards, N. J., & Aronowski, J. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1685-15.2015 · Cited by 295
Eikermann-Haerter, K., Dileköz, E., Kudo, C., Savitz, S. I., Waeber, C., Baum, M. J., Ferrari, M. D., van den Maagdenberg, A. M. J. M., Moskowitz, M. A., & Ayata, C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36059 · Cited by 283
Molecular Mechanisms of Apoptosis in Cerebral Ischemia: Multiple Neuroprotective Opportunities
Nakka, V. P., Gusain, A., Mehta, S. L., & Raghubir, R. (2008) · Molecular Neurobiology · doi:10.1007/s12035-007-8013-9 · Cited by 261
Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage
YI, J., PARK, S., KAPADIA, R., & VEMUGANTI, R. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.019 · Cited by 206
Self-citationFXR ligands protect against hepatocellular inflammation via SOCS3 induction
Xu, Z., Huang, G., Gong, W., Zhou, P., Zhao, Y., Zhang, Y., Zeng, Y., Gao, M., Pan, Z., & He, F. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.04.015 · Cited by 71
All’s well that transcribes well: Non-coding RNAs and post-stroke brain damage
Vemuganti, R. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.07.014 · Cited by 71
Self-citationWojtowicz, A. K., Szychowski, K. A., & Kajta, M. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9434-z · Cited by 62
“The protective effects of PPAR-c agonists have been shown in many experimental models of brain injury, including cerebral ischemia (Shimazu et al. 2005; Chu et al. 2006; Pereira et al. 2006; Tureyen et al. 2007; Zhao et al. 2009; Kim et al. 2011), NMDA-induced cytotoxicity (Zhao et al.”
Background
Metadata
- Authors
- Tureyen, K., Kapadia, R., Bowen, K. K., Satriotomo, I., Liang, J., Feinstein, D. L., & Vemuganti, R.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-04
- Volume
- 101
- Issue
- 1
- Pages
- 41-56
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1534334215
- Cited by
- 199
- References
- 4
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.